Our Strategies

Life Science Strategy

Our Life Science strategy draws upon the extensive scientific backgrounds and investment experience of ArrowMark’s life science team, led by Dr. Tony Yao, M.D. and Ph.D. to identify pre-IPO and early stage public life science companies focused on advancing novel therapeutic agents and drug discovery/research technologies aimed at improving the standard of medical care and quality of patient life.

Adhering to a science-driven investment philosophy and fundamental research process, the strategy pursues a multi-stage investment approach, seeking to provide strategic guidance and long-term, value-added capital throughout a company’s clinical development path.

Investment Team

Tony Yao, M.D., Ph.D.

Portfolio Manager


Investment Analyst

Matt Eckler, Ph.D.

Investment Analyst

Contact ArrowMark Investor Relations